NCT03129061 2022-12-05
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
CellSight Technologies, Inc.
Phase 1 Completed
CellSight Technologies, Inc.
Memorial Sloan Kettering Cancer Center